Form 4: Sangamo Officer's Tax-Related Stock Dispositions

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, reported the disposition of shares for mandatory tax withholding following RSU vesting.

Summary

• Nikunj Jain, Principal Accounting Officer of Sangamo Therapeutics, Inc. (SGMO), reported two dispositions of common stock.
• On February 24, 2026, 666 shares were surrendered for mandatory tax withholding purposes at a price of $0.4725 per share, related to a restricted stock unit (RSU) grant that vested on that date.
• Following this transaction, Nikunj Jain beneficially owned 242,330 shares.
• On February 25, 2026, an additional 5,119 shares were surrendered for mandatory tax withholding at a price of $0.47 per share, related to another RSU grant that vested on that date.
• After both reported transactions, Nikunj Jain beneficially owned 237,211 shares.
• These dispositions were solely for mandatory tax withholding and do not represent discretionary trades by the reporting person.
• Remaining RSU grants from February 24, 2023, and February 25, 2025, will continue to vest in future installments, subject to continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the reported dispositions are routine tax-related transactions upon RSU vesting and do not indicate a discretionary sale or change in the officer's outlook on the company.

Future Outlook

Remaining RSU grants from February 24, 2023, and February 25, 2025, will continue to vest in successive equal quarterly installments, subject to the reporting person's continuous service through each such date and potential acceleration as provided in the 2018 Equity Incentive Plan.

Management Comments

• The reported transactions represent shares surrendered by the Reporting Person solely for mandatory tax withholding purposes.
• These transactions do not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing tax-related dispositions of restricted stock units are common for executives in publicly traded companies, particularly in the biotechnology sector where equity compensation is a significant component of remuneration. These transactions are typically non-discretionary and do not reflect a change in management's investment sentiment.

Comparison to Industry Standards

• These types of tax-related dispositions upon RSU vesting are standard practice across all industries for executives receiving equity compensation. They are routine compliance filings and do not offer specific comparative insights against other companies' operational or financial performance.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are non-discretionary tax transactions and do not signal a change in the officer's investment conviction.
• Employees (specifically the reporting person): The reporting person's equity compensation has vested, leading to a tax obligation fulfilled by share disposition.

Next Steps

• Remaining RSU grants from February 24, 2023, and February 25, 2025, will vest in successive equal quarterly installments, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing reports routine, non-discretionary stock dispositions for tax withholding purposes following RSU vesting. Such transactions are standard for executive compensation and do not provide new information to warrant a change in investment thesis. The filing itself does not offer insights into the company's operational performance or future prospects that would influence a buy or sell decision, thus a 'hold' recommendation is appropriate based solely on this specific filing.

Keywords

Sangamo Therapeutics, SGMO, Form 4, insider transaction, stock disposition, RSU vesting, tax withholding, executive compensation